Abstract

Aim: QTc interval prolongation has been found in HIV-infected patients. There are contradictory reports about the effects of antiretroviral drugs on QT interval duration. The aim of the study was to assess if the prolongation of the QTc interval depends on the antiretroviral treatment and other risk factors related to HIV infection. Material/Methods: 283 adult HIV-infected patients treated in HIV Outpatient Clinic in Warsaw were enrolled in the prospective, single-centre study. Factors related to ART and HIV infection were collected. Electrocardiograms were performed for each patient and QTc interval duration was measured and corrected using Bazett’s heart rate formula. Results: Prolonged QTc interval was identified in 4.9 % HIV-infected patients (median age 34.5 years, 85% male, 89% HIV RNA<50 copies/mL). The average length of QTc interval in ART HIV(+) patients was 403 ms, in untreated HIV(+) subjects – 398ms and in the control group of healthy individuals – 400ms. ART regimen included PI in 47.4% cases, NNRTI in 24.1% and INI in 28.5% patients. The longest QTc interval was found in patients treated with the PI scheme – 408 ms, shorter with INI – 399ms and with NNRTI – 397ms. A multivariable analysis revealed that only older age and female gender were significantly associated with QTc prolongation. Conclusions: In the group of young, asymptomatic HIV-infected patients with good immunovirological control, the prevalence of QTc prolongation was low – only 4.9% of subjects. ARV treatment seem to have no significant influence on the QTc interval duration.

References

• 1. Allavena C., Jacob N., Gourrault J., Billaud E., Sécher S., RaffiF., Lamirault G.: Impact of HIV infection and antiretrovirals onQT interval: the HIMPAQT study. JIAS, 2018; S8: e25187
  Google Scholar
• 2. Anson B.D., Weaver J.G., Ackerman M.J., Akinsete O., HenryK., January C.T., Badley A.D.: Blockade of HERG channels by HIVprotease inhibitors. Lancet, 2005; 365: 682-686
  Google Scholar
• 3. Benton T.D.: Depression and HIV/AIDS. Curr. Psychiatr. Rep.,2008; 10: 280-285
  Google Scholar
• 4. Bing E.G., Burnam M.A., Longshore D., Fleishman J.A., Sherbourne C.D., London A.S., Turner B.J., Eggan F., Beckman R., VitielloB., Morton S.C., Orlando M., Bozzette S.A., Ortiz-Barron L., ShapiroM.: Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch. Gen.Psychiatry, 2001; 58: 721-728
  Google Scholar
• 5. Butt A.A., Chang C.C., Kuller L., Goetz M.B., Leaf D., RimlandD., Gibert C.L., Oursler K.K., Rodriguez-Barradas M.C., Lim J., KazisL.E., Gottlieb S., Justice A.C., Freiberg M.S.: Risk of heart failurewith human immunodeficiency virus in the absence of priordiagnosis of coronary heart disease. Arch. Intern. Med., 2011;171: 737-743
  Google Scholar
• 6. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillancecase definition for AIDS among adolescents and adults. MMWR,1992; 41 (No. RR-17)
  Google Scholar
• 7. Charbit B., Rosier A., Bollens D., Boccara F., Boelle P.Y., Koubaa A., Girard P.M., Funck-Brentano C.: Relationship betweenHIV protease inhibitors and QTc interval duration in HIV-infected patients: a cross-sectional study. Br. J. Clin. Pharmacol.,2009; 67: 76-82
  Google Scholar
• 8. Chinello P., Lisena F.P., Angeletti C., Boumis E., Papetti F., Petrosillo N.: Role of antiretroviral treatment in prolonging QTcinterval in HIV-positive patients. J. Infect., 2007; 54: 597-602
  Google Scholar
• 9. Chow D.C., Wood R., Choi J., Grandinetti A., Gerschenson M.,Sriratanaviriyakul N., Nakamoto B., Shikuma C., Low P.: Cardiovagal autonomic function in HIV-infected patients with unsuppressed HIV viremia. HIV Clin. Trials, 2011; 12: 141-150
  Google Scholar
• 10. Cichoż-Lach H., Tomaszewski M., Kowalik A., Lis E., Tomaszewski A., Lach T, Boczkowska S., Celiński K.: QT interval prolongation and QRS voltage reduction in patients with liver cirrhosis.Adv. Clin. Exp. Med., 2015; 24: 615-622
  Google Scholar
• 11. Gil M., Sala M., Anguera I., Chapinal O., Cervantes M., GumaJ.R., Segura F.: QT prolongation and torsades de pointes in patientsinfected with human immunodeficiency virus and treated withmethadone. Am. J. Cardiol., 2003, 92: 995-997
  Google Scholar
• 12. Hunt K., Hughes C.A., Hills-Nieminen C.: Protease inhibitorassociated QT interval prolongation. Ann. Pharmacother., 2011;45: 1544-1550
  Google Scholar
• 13. Kocheril A.G., Bokhari S.A., Batsford W.P., Sinusas A.J.: LongQTc and torsades de pointes in human immunodeficiency virusdisease. Pacing Clin. Electrophysiol., 1997; 20: 2810-2816
  Google Scholar
• 14. Lekakis J., Ikonomidis I.: Cardiovascular complications of AIDS.Curr. Opin. Crit. Care, 2010; 16: 408-412
  Google Scholar
• 15. Marzolini C., Back D., Weber R., Furrer H., Cavassini M., CalmyA., Vernazza P., Bernasconi E., Khoo S., Battegay M., Elzi L.: Ageingwith HIV: medication use and risk for potential drug-drug interactions. J. Antimicrob. Chemother., 2011; 66: 2107-2111
  Google Scholar
• 16. Miller C.D., El-Kholi R., Faragon J.J., Lodise T.P.: Prevalence andrisk factors for clinically significant drug interactions with antiretroviral therapy. Pharmacotherapy, 2007; 27: 1379-1386
  Google Scholar
• 17. Monsuez J.J., Gallet B., Escaut L., Vayre F., Pulik M., CharniotJ. C., Merad M., Slama M., Webers S., Vittecoq D.: Cardiac side effects of anti-HIV agents. Arch. Mal. Coeur. Vaiss., 2000; 93, 835-840
  Google Scholar
• 18. Moreno T., Pérez I., Isasti G., Cabrera F., Santos J., Palacios R.:Prevalence and factors associated with a prolonged QTc intervalin a cohort of asymptomatic HIV-infected patients. AIDS Res. Hum.Retroviruses, 2013; 29: 1195-1198
  Google Scholar
• 19. Moss A.J.: Measurement of the QT interval and the risk associated with QTc in interval prolongation: a review. Am. J. Cardiol.,1993; 72: 23-25
  Google Scholar
• 20. Moss A.J.: The QT interval and torse de pointes. Drug Saf.,1999; 21, 5-10
  Google Scholar
• 21. Moss A.J., Robinson J.: Clinical features of the idiopathic longQT syndrome. Circulation, 1992; 85 (Suppl.): 1140-1144
  Google Scholar
• 22. Nordin C., Kohli A., Beca S., Zaharia V., Grant T., Leider J., Marantz P.: Importance of hepatitis C coinfection in the developmentof QT prolongation in HIV-infected patients. J. Electrocardiol.,2006, 39: 199-205
  Google Scholar
• 23. Patel N., Abdelsayed S., Veve M., Miller C.D.: Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens. Ann. Pharmacother., 2011; 45: 317-324
  Google Scholar
• 24. Patel N., Veve M., Kwon S., McNutt L.A., Fish D., Miller C.D.:Frequency of electrocardiogram testing among HIV-infected patients at risk for medication-induced QTc prolongation. HIV Med.,2013; 14: 463-471
  Google Scholar
• 25. Pulik P., Horban A.: Zasady opieki nad zakażonymi HIV. Warszawa PTN AIDS 2018. ISBN 978-83-948074-0-5. Leczenie antyretrowirusowe: 66-74
  Google Scholar
• 26. Rasmussen L.D., May M.T., Kronborg G., Larsen C.S., Pedersen C.,Gerstoft J., Obel N.: Time trends for risk of severe age-related diseasesin individuals with and without HIV infection in Denmark: a nationwide population-based cohort study. Lancet HIV, 2015; 2: e288-e298
  Google Scholar
• 27. Rawdanowicz J., Pikto-Pietkiewicz W., Marczyńska M.: Cardiovascular diseases associated with HIV infection and their management. Kardiol. Pol., 2013; 71: 1183-1187
  Google Scholar
• 28. Reinsch N., Buhr C., Krings P., Kaelsch H., Neuhaus K., WienekeH., Erbel R., Neumann T., German Heart Failure Network: Prevalenceand risk factors of prolonged QTc interval in HIV-infected patients:results of the HIV-HEART study. HIV Clin. Trials, 2009; 10: 261-268
  Google Scholar
• 29. Roden D.M.: Drug-induced prolongation of the QT interval. N.Engl. J. Med., 2004; 350: 1013-1022
  Google Scholar
• 30. Sani M.U., Okeahialam B.N.: QTc interval prolongation in patients with HIV and AIDS. J. Natl. Med. Assoc., 2005; 97: 1657-1661
  Google Scholar
• 31. Sawicka-Parobczyk M., Bieganowska K.: The QT/QTc intervalon the electrocardiogram: An important parameter and a difficultassessment. Forum Med. Rodz., 2010; 1: 17-25
  Google Scholar
• 32. Soliman E.Z., Lundgren J.D., Roediger M.P., Duprez D.A., Temesgen Z., Bickel M., Shlay J.C., Somboonwit C., Reiss P., Stein J.H., Neaton J.D., INSIGHT SMART Study Group: Boosted protease inhibitorsand the electrocardiographic measures of QT and PR duration. AIDS,2011; 25, 367-377
  Google Scholar
• 33. Warriner A.H., Burkholder G.A., Overton E.T.: HIV-related metabolic comorbidities in the current ART era. Infect. Dis. Clin. NorthAm., 2014; 28: 457-476
  Google Scholar
• 34. Yap Y.G., Camm J.: Risk of torsades de pointes with non-cardiacdrugs. Doctors need to be aware that many drugs can cause qt prolongation. BMJ, 2000; 320, 1158-1159
  Google Scholar
• 35. Zareba W.: Drug induced QT prolongation. Cardiol. J., 2007; 14:523-533
  Google Scholar

Full text